Create a free account and describe your company. With the trial, CanPursue checks every opportunity against it and explains the fit.
Create free accountCreate a free account to see past contracts like this one: who won and at what price.
Create free accountTrade Agreement: Agreement on Internal Trade (AIT) Tendering Procedures: Generally only one firm has been invited to bid Non-Competitive Procurement Strategy: Exclusive Rights Comprehensive Land Claim Agreement: No Vendor Name and Address: GlaxoSmithKline Inc. 7333 Mississauga Road North Mississauga Ontario Canada L5N6L4 Nature of Requirements:
Canada proposes to establish a contract with GlaxoSmithKline Inc. on behalf of the Federal/Provincial/Territorial (F/P/T) Group Purchasing Program for Drugs and Vaccines. The contract is to supply Japanese Encephalitis Vaccine, on an as and when requested basis to the federal/provincial/territorial (F/P/T) jurisdictions.
The estimated requirement is 700 doses for firm year.
April 1, 2016 to March 31, 2017, with an option to extend the contract period for two additional one-year periods.
Will be on an as-and-when requested basis.
The provisions of the World Trade Organization-Agreement on Government Procurement (WTO-AGP), North American Free Trade Agreement (NAFTA), Canada-Chile Free Trade Agreement (CCFTA) and Canada-Columbia Free Trad e Agreement Canada- Peru Free Trade (FTA) are not applicable for reasons connected with the protection of human life and health (see NAFTA article 1018 para. 2 (a) and (b); WTO-AGP article XXIII (2); CC FTA Article Kbis 16-2(b); and FTA article 1402 para. 2(b) ), and because of the absence of regulatory harmonization between Canada and the other signatory countries to the WTO, NAFTA CCFTA , and FTA . This requirement is subject to the Agreement on Internal Trade (AIT).
This requirement is for the Federal/Provincial/Territorial (F/P/T) Group Purchasing Program for Drugs and Vaccines. Canada is acting as a purchasing agent for Provincial and/or Territorial Governments.
It is intended to negotiate directly with GlaxoSmithKline Inc. as they are the only known source of supply licensed by Health Canada’s Biologics and Genetic Therapies Directorate (BGTD) to supply in Canada.
Delivery Date: 26/11/2015
You are hereby notified that the government intends to negotiate with one firm only as identified above. Should you have any questions concerning this requirement, contact the contracting officer identified above.
An Advance Contract Award Notice (ACAN) allows departments and agencies to post a notice, for no less than fifteen (15) calendar days, indicating to the supplier community that it intends to award a good, service or construction contract to a pre-identified contractor. If no other supplier submits, on or before the closing date, a Statement of Capabilities that meets the requirements set out in the ACAN, the contracting authority may then proceed with the award. However, should a Statement of Capabilities be found to meet the requirements set out in the ACAN, then the contracting authority will proceed to a full tendering process.
Suppliers who consider themselves fully qualified and available to provide the services/goods described herein, may submit a statement of capabilities in writing to the contact person identified in this Notice on or before the closing date of this Notice. The statement of capabilities must clearly demonstrate how the supplier meets the advertised requirements.
The PWGSC file number, the contracting officer's name and the closing date of the ACAN must appear on the outside of the envelope in block letters or, in the case of a facsimile transmission, on the covering page.
The Crown retains the right to negotiate with suppliers on any procurement.
Documents may be submitted in either official language of Canada.
Not stated in the notice: procurement type, procurement method, selection criteria, region of delivery, region of opportunity, expected contract period, end user
No amendments observed.
No attachments listed in the open data.
No contact listed in the open data.